NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Myxoid/round cell liposarcoma (MRCL) is the second most common liposarcoma subtype, accounting for >33% of liposarcomas and approximately 10% of all soft tissue sarcomas. Although MRCL is a chemosensitive subtype, patients with metastatic disease have a poor outcome. NY‐ESO‐1 is a cancer‐testis antigen (also known as cancer germ cell antigen) that has been successfully targeted in vaccine trials and in adoptive T‐cell therapy trials for the treatment of several solid tumors. METHODS: The authors investigated the feasibility of targeting NY‐ESO‐1 in patients with MRCL by evaluating the prevalence of NY‐ESO‐1 expression in tumors using immunohistochemistry and quantitative reverse transcriptase‐polymerase chain reaction analysis. NY‐ESO‐1–specific tumor recognition by NY‐ESO‐1–specific T‐cells also was analyzed using a chromium release assay. RESULTS: A search of the University of Washington Sarcoma Tissue Bank identified paraffin‐embedded tumor samples from 25 patients with MRCL. NY‐ESO‐1 expression was observed in every MRCL tumor assessed (100%); in 18 tumors (72%), staining was homogenous. In all but 2 tumors, staining was sufficiently robust (2+) that such patients would be eligible for clinical trials of NY‐ESO‐1–directed therapy. By using NY‐ESO‐1 specific, CD8‐positive T‐cells, the in vitro sensitivity of myxoid liposarcoma cell lines to antigen‐specific lysis was demonstrated. CONCLUSIONS: The current results establish NY‐ESO‐1 as an important target antigen for the treatment of patients with MRCL. Cancer 2012. © 2012 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., et al. (1992) · Nature · doi:10.1038/359162a0 · Cited by 1,907
RNA targets of wild-type and mutant FET family proteins
Hoell, J. I., Larsson, E., Runge, S., Nusbaum, J. D., Duggimpudi, S., Farazi, T. A., Hafner, M., Borkhardt, A., Sander, C., & Tuschl, T. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2163 · Cited by 350
Cited by
D'Angelo, S. P., Melchiori, L., Merchant, M. S., Bernstein, D., Glod, J., Kaplan, R., Grupp, S., Tap, W. D., Chagin, K., Binder, G. K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1417 · Cited by 435
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Thomas, R., Al-Khadairi, G., Roelands, J., Hendrickx, W., Dermime, S., Bedognetti, D., & Decock, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00947 · Cited by 393
Clinical and Molecular Spectrum of Liposarcoma
Lee, A. T. J., Thway, K., Huang, P. H., & Jones, R. L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.9598 · Cited by 372
Self-citationPollack, S. M., He, Q., Yearley, J. H., Emerson, R., Vignali, M., Zhang, Y., Redman, M. W., Baker, K. K., Cooper, S., Donahue, B., et al. (2017) · Cancer · doi:10.1002/cncr.30726 · Cited by 274
Self-citationCancer testis antigens in sarcoma: Expression, function and immunotherapeutic application
Wei, R., Dean, D. C., Thanindratarn, P., Hornicek, F. J., Guo, W., & Duan, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.024 · Cited by 48
Metadata
- Authors
- Pollack, S. M., Jungbluth, A. A., Hoch, B. L., Farrar, E. A., Bleakley, M., Schneider, D. J., Loggers, E. T., Rodler, E., Eary, J. F., Conrad, III, Jones, R. L., & Yee, C.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2012-02-22
- Volume
- 118
- Issue
- 18
- Pages
- 4564-4570
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1572718168
- Cited by
- 125
- References
- 2
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. https://app.cochat.ai/papers/10.1002/cncr.27446
- The paper
- Pollack, S. M., Jungbluth, A. A., Hoch, B. L., Farrar, E. A., Bleakley, M., Schneider, D. J., Loggers, E. T., Rodler, E., Eary, J. F., Conrad, III, Jones, R. L., & Yee, C. (2012). NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer. https://doi.org/10.1002/cncr.27446
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.